Haichang Biotech Completes Nearly RMB 500 Million Series C Financing to Advance Nucleic Acid Therapeutics and Drug Delivery Platforms
Haichang Biotech
Innovative Formulation Developer
Recently, Haichang Biotech (hereinafter referred to as "Haichang Biotech") announced the completion of its Series C financing. The total amount of this round of financing is nearly 500 million RMB, led by SDIC (Guangdong) Technology Achievement Transformation Venture Capital Fund, with participation from Jianyuan Shunda (Hangzhou) Equity Investment Fund, Dongguan Songshan Lake Science City Equity Investment Fund, Zhejiang Province's "4+1" Biopharmaceuticals and High-end Medical Devices Industry Fund, and Sinobioway Biomedicine Co., Ltd. This round of financing will focus on nucleic acid innovative drug pipelines, the research and development of new extrahepatic delivery systems, clinical trials, and accelerating production base and capacity construction.
As a national-level specialized and new "little giant" enterprise, Haichang Biotech focuses on the development and industrial application of drug delivery system technology, and has built the QTsome with independent intellectual property rights.®and other technical platforms. Currently, the company has successfully broken through the international nucleic acid delivery patent barriers, achieving a breakthrough in key "bottleneck" technologies. HC0301, an innovative small nucleic acid drug for primary liver cancer developed based on the company's existing technology platforms, has entered Phase II clinical trials in international multicenter studies in China (including Hong Kong, China), the United States, and other regions, becoming a global leader in small nucleic acid oncology.One of the fastest advancing pipelines in the field of precision treatment.The world's first, based on lipid nanoparticles (QTsome®) The next-generation TLR9 immunostimulant HC016 lipid complex injection, developed by Haichang Biotech, has received IND approvals in both China and the United States.Entering Phase I clinical trials, with Best-in-Class (BIC) potential, demonstrating strong innovative capabilities. Meanwhile, the company has several potential First-in-Class (FIC) nucleic acid drug pipelines under research, including in vivo cell editing.Innovative Therapy.
In the field of complex injectables, the company's key product, albumin-bound paclitaxel for injection, has been approved for marketing in nearly 40 countries and regions, including China, the EU, the UK, and Peru. The dual production sites of CR Double-Crane Tiantong Pharmaceutical and Kexing Pharmaceutical have simultaneously passed the EU cGMP certification, leading the internationalization process of China's high-end formulations. Several other complex injectable products are also about to be launched.
Dr. Xiaobin Zhao, Chairman and Founder of Haichang Biotech, stated: "This round of financing reflects the market's full recognition of the company's core technology advantages and strategic value, and will also provide strong support for Haichang Biotech's long-term development strategy. We will focus on QTsome..."®Using delivery platforms as strategic pivots, Haichang Biotech has built a closed-loop system for the research, development, production, and commercialization of high-end complex injectables and nucleic acid innovative drugs. By empowering core products with capital for global layout, and driven by technological innovation, the company continuously breaks through key technical bottlenecks in the industry, contributing to the transformation of the global pharmaceuticals sector.
This round of financing has garnered support from institutions such as SDIC Venture Capital, CCB Investment, Songshan Lake Venture Capital, Hedajin Financial Services, and Kexing Biotech, forming a multi-dimensional capital matrix of "national capital strategy leadership + local industrial capital collaboration + industry chain co-construction." Focused on accelerating the transformation of major scientific and technological achievements and their industrialized, large-scale application, the company aims to cultivate and strengthen strategic emerging industries while establishing itself as an industry benchmark. Moving forward, the company will continue to introduce strategic investments from domestic and international professional biopharmaceutical investment institutions, building a trinity global innovation ecosystem of "technology-capital-industry." Through the efficient integration of strategic resources and the steady advancement of a global layout, the company is comprehensively enhancing its core competitiveness. It is committed to becoming a key player in the field of international pharmaceutical innovation, providing innovative treatment solutions with greater clinical value for patients worldwide.
SDIC Venture Capital is a venture capital fund management company specifically established by the State Development & Investment Corporation (SDIC) to implement the national innovation-driven development strategy, deepen the comprehensive strategic cooperation with the Ministry of Science and Technology, and accelerate the transfer and transformation of national scientific and technological achievements in a market-oriented manner. SDIC (Guangdong) Technology Achievement Transformation Venture Capital Fund Partnership (Limited Partnership) was jointly initiated by the Ministry of Science and Technology, SDIC Group, local governments, financial institutions, and other parties, with SDIC Venture Capital serving as the fund manager. The fund consistently focuses on the investment goal of transforming scientific and technological achievements, concentrating on key areas such as advanced manufacturing, electronic information, biomedicine, materials, and energy. It continuously promotes the independent innovation of core technologies to achieve breakthroughs and build a sound investment ecosystem for the transformation of scientific and technological achievements.
Jianyuan Shunda (Hangzhou) Equity Investment Fund Partnership (Limited Partnership) is a wholly-owned subsidiary of China Construction Bank.— Established by CCB Financial Asset Investment Co., Ltd., the fund focuses on technological innovation, with key investments in cutting-edge sectors such as artificial intelligence, intelligent manufacturing, the Internet of Things, biomedicine, high-end equipment, new materials, and green energy. It fully leverages the comprehensive financial service capabilities of a leading state-owned bank to build a "technology-Industry-The "financial" linkage mechanism provides support for Hangzhou's development of new quality productive forces.
Dongguan Songshan Lake Science City Equity Investment Partnership (Limited Partnership) is a pre-IPO fund managed by Dongguan Songshan Lake Science City Co., Ltd. ("Science City Company"), focusing on industrial investment and industry cultivation within the "1+4+1+X" modern industrial system of Songshan Lake. The Science City Company, a wholly state-owned enterprise in the Songshan Lake Park, undertakes the corporate mission of development and construction, park industrial development, and urban comprehensive operations, concentrating on five major business sectors: industrial operations, industrial investment, commerce and cultural tourism, engineering construction, and urban operations.
Zhejiang Province“4+1"The Biopharmaceutical and High-end Medical Device Industry Fund was established in2023Year10Month, Total Scale50100 million yuan (initial scale20billion yuan), managed by the subsidiary of Qiantang Industrial Group and Hedda Financial's private equity fund management company as the manager andGP1, Jintou Shengyuan, a subsidiary of Zhejiang Golden Control, asGP2Jointly participate in management, with the fund focusing on key areas of Zhejiang Province's modern consumption and large health industry, committed to building a full industry chain ecosystem. Investments have been made currently.17This item,5Only Child Fund, Investment Amount11.89100 million yuan. Ranked in the "Miao Ying Biotechnology Medical Health Investment Excellence List"2024"Annual Healthcare Best New Investment Institution"
Sinovac Biotech Co., Ltd. (Abbreviation: Sinovac Pharma, Stock Code:688136) is an innovative international biopharmaceutical company mainly engaged in the research, production, and sales integration of recombinant protein drugs and microecological preparations. Focusing on treatment areas such as antiviral, oncology and immunology, hematology, gastroenterology, and degenerative diseases, it builds cutting-edge biotechnology platforms for novel proteins, novel antibodies, and nucleic acid drugs, adhering to "innovation.+Internationalization"A platform-based development model driven by dual engines, while exploring the wide application of biotechnology in the healthcare sector, actively nurturing and incubating new industries, committed to becoming a leader in high-quality biopharmaceuticals and serving patients worldwide."
Haichang Biotech, located in the China Medical Valley in Hangzhou, is a national specialized and innovative enterprise driven by biopharmaceutical technology innovation, integrating research, production, and sales.“Little Giant”Enterprise. The company upholds“Share, Progress, Truth-seeking, Pragmatism”The core values, focusing on the technical development and industrial application of drug delivery systems, with a product pipeline covering oncology,Metabolic diseases,Analgesia and infectious diseases, among othersDiseaseField.
E.N.D
ForPromote Cooperation and Technical Exchange in the Cell and Gene Therapy IndustryThe team of the WeChat Official Account "Cell and Gene Therapy Field" has established a professional communication group for cell and gene therapy. Press and hold the QR code below to add the editor's WeChat and join the group. Due to the large number of applicants, please include the following information when adding WeChat: Institution/Enterprise—Major/Position—Name. If you are a PI/Professor/Manager or above, please also indicate.
Previous article recommendations:(Click the article title below to open the original text)
1.1 Billion Yuan! WestGene LNP Licensed to BGI FireEye for mRNA Drug Development
A Cell Therapy Company in China Completes A+ Round Financing
Another AAV Gene Therapy Drug Submitted for Marketing Approval in China
A Gene and Cell Therapy Company in China Initiates Sci-Tech Innovation Board IPO
¥93,000/bottle! The pricing of China's first marketed AAV gene therapy drug is announced
Over $2.1 Billion! Keyi Pharmaceuticals' Cell Therapy Drug Goes Global
Stock Price Surges Over 700%! A Breakthrough in Cell Therapy Product Achieved